Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

NETWORK

Sponsor class

Conditions

Gastric Neuroendocrine Carcinoma
Intestinal Neuroendocrine Carcinoma
Pancreatic Neuroendocrine Carcinoma

Interventions

DRUG: Capecitabine
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Etoposide
OTHER: Laboratory Biomarker Analysis
DRUG: Temozolomide

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]